Our Vision
We care deeply about addressing systemic injustices that deprive people of basic rights. We believe that regardless of income, race, gender, sexuality, or any other circumstances of birth, no one should have to forgo healthcare due to a lack of resources.
Starting with Sickle Cell Disease (SCD), we will apply our proprietary 3D phase imaging microscope and deep learning algorithms to empower patients and their providers to take a proactive, rather than reactive, approach to managing their health.
Sickle Cell Disease
(by the numbers)
people affected around the world
30 M
preventable deaths every year
170,000
shorter life expectancy
33 YEARS
of hospitalization each year
13+ DAYS
in lifetime treatment costs
$1M - $9M
Our Solution
KovaDx is building a tool that will allow for ongoing monitoring and preventative care for individuals with rare blood diseases.
Our device utilizes 3D Quantitative Phase Imaging (QPI) to obtain data about human red blood cells to create a Red Blood Cell Health Index.
Bridging the Divide
Decrease in childhood mortality in low-income countries by Increasing access to affordable and accurate lifesaving diagnostics at birth.
Significantly improve quality of life for patients living with sickle cell disease in the U.S. and other high-income countries by preventing debilitating sickling crises.
Accelerate much-needed research for sickle cell disease by building first of its kind database of 3D-phase images of sickle cells.
Why Now
Change in Tide of Historic Underinvestment
Investment into health equity and access in recent years, in response to a national reckoning around racial injustice, has impacted funding and investment into Sickle Cell Disease.
Covid Pandemic and Remote Care
The Covid pandemic has demonstrated the need for and promise for decentralized models of care and access.
Advances in Technology
Exponential advances in AI have made it possible to process the amount of data our system is capable of in a short amount of time.
Evolving Pharmacotherapeutic Landscape
There are only few FDA-approved drugs to treat SCD, illustrating the high unmet need for new therapies. The presence of strong key market players with strong pipelines predicts market growth.